Fidson Healthcare PLCFIDSON:LAG

0.11 / 4.85%
30.00 %
Latest price in NGNToday's changeShares traded1 year changeBeta
Data delayed at least 60 minutes, as of Jun 30 2016 14:28 BST.

About the company

Revenue in NGN (TTM)Net income in NGNIncorporatedEmployees
Fidson Healthcare PLC
268, Ikorodu Road, Shomolu
P.O.Box 7210
Phone+234 3429102Fax+234 3429106Website
Fidson Healthcare Plc is a Nigeria-based pharmaceutical manufacturing company. The principal activities of the Company are the manufacture and distribution of pharmaceutical products. The Company's segments include over the counter, ethical product and consumer. The over the counter segment represents the products that may be sold directly to the consumer without a prescription. The ethical products segment represents the drugs, which would be sold to the consumer only on the possession of a valid prescription. The consumer segment represents household items. The Company offers various drug products and formulations across different therapeutic classes and pharmacological segments, which include antacid and ulcer care; anti-diabetic; anti-malaria; cardio-vascular; cough, cold, catarrh and allergies; multivitamin-hematinics; nuero-psychiatry/anti-physiotic; anti-diarrhea; osteo-care; pain-relievers, and thrombo-prophalyti.

Mergers & acquisitions

There are no recent mergers or acquisitions for Fidson Healthcare PLC.
Data delayed at least 60 minutes, as of Jun 30 2016 14:28 BST.

Peer analysis

There are no peers analysis for Fidson Healthcare PLC.

Institutional shareholders

HolderShares% Held
Nomura Asset Management U.K. Ltd.
as of 31 Dec 2015
Per cent of shares
held by top holders
Data from 31 Jan 2016 - 31 Jan 2016Source: FactSet Research Systems Inc.
© Thomson Reuters Click for restrictions.

All markets data located on is subject to the FT Terms & Conditions.

All content on is for your general information and use only and is not intended to address your particular requirements. In particular, the content does not constitute any form of advice, recommendation, representation, endorsement or arrangement by FT and is not intended to be relied upon by users in making (or refraining from making) any specific investment or other decisions.

Any information that you receive via is at best delayed intraday data and not "real time". Share price information may be rounded up/down and therefore not entirely accurate. FT is not responsible for any use of content by you outside its scope as stated in the FT Terms & Conditions.

  • Exchange:Nigerian Stock Exchange